ArticleJournal for immunotherapy of cancer2026

Pharmacologic targeting of the dopamine D2 receptor impacts the efficacy of immune checkpoint blockade in melanoma.

Mark Gregory et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.